TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

BACKGROUND: Patients with diabesity have a significantly increased risk of developing cardiovascular disease. Therefore, therapy addressing the multiple metabolic abnormalities linked with diabesity and leading to further reduction of cardiovascular risk is highly desirable. Activation of the TGR5 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambad, Shitalkumar P, Tuli, Davinder, Mathur, Anoop, Ghalsasi, Sameer A, Chaudhary, Anita R, Deshpande, Shailesh, Gupta, Ramesh C, Chauthaiwale, Vijay, Dutt, Chaitanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873233/
https://www.ncbi.nlm.nih.gov/pubmed/24379686
http://dx.doi.org/10.2147/DMSO.S50209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873233/
https://www.ncbi.nlm.nih.gov/pubmed/24379686
http://dx.doi.org/10.2147/DMSO.S50209

Ejemplares similares